Source:http://linkedlifedata.com/resource/pubmed/id/16410446
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2006-5-4
|
| pubmed:abstractText |
We aimed to compare AIDS risk-adapted intensive chemotherapy in AIDS-related lymphoma (ARL) patients before and after the advent of highly active antiretroviral therapy (HAART). A total of 485 patients aged from 18 to 67 years were randomly assigned to chemotherapy after stratification according to an HIV score based on performance status, prior AIDS, and CD4(+) cell counts below 0.10 x 10(9)/L (100/mm(3)). A total of 218 good-risk patients (HIV score 0) received ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisolone) or CHOP (doxorubicin, cyclophosphamide, vincristine, and prednisolone); 177 intermediate-risk patients (HIV score 1), CHOP or low-dose CHOP (Ld-CHOP); and 90 poor-risk patients (HIV score 2-3), Ld-CHOP or VS (vincristine and steroid). The 5-year overall survival (OS) in the good-risk group was 51% for ACVBP versus 47% for CHOP (P = .85); in the intermediate-risk group, 28% for CHOP versus 24% for Ld-CHOP (P = .19); and in the poor-risk group, 11% for Ld-CHOP versus 3% for VS (P = .14). The time-dependent Cox model demonstrated that the only significant factors for OS were HAART (relative risk [RR] 1.6, P < .001), HIV score (RR 1.7, P < .001), and the International Prognostic Index (IPI) score (RR 1.5, P < .001) but not chemotherapy regimen. Our findings indicate that in ARL patients, HIV score, IPI score, and HAART affect survival but not the intensity of the CHOP-based chemotherapy.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0006-4971
|
| pubmed:author |
pubmed-author:BoslyAndreA,
pubmed-author:CarboneAntoninoA,
pubmed-author:ChichinoGuidoG,
pubmed-author:CoiffierBertrandB,
pubmed-author:GabarreJeanJ,
pubmed-author:GisselbrechtChristianC,
pubmed-author:GolfierJean-BaptisteJB,
pubmed-author:MounierNicolasN,
pubmed-author:RaphaelMartineM,
pubmed-author:RizzardiniGiulianoG,
pubmed-author:SpinaMicheleM,
pubmed-author:TirelliUmbertoU,
pubmed-author:VaccherEmanuelaE
|
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
107
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
3832-40
|
| pubmed:dateRevised |
2007-1-9
|
| pubmed:meshHeading |
pubmed-meshheading:16410446-Adult,
pubmed-meshheading:16410446-Aged,
pubmed-meshheading:16410446-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16410446-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:16410446-CD4 Lymphocyte Count,
pubmed-meshheading:16410446-Cyclophosphamide,
pubmed-meshheading:16410446-Doxorubicin,
pubmed-meshheading:16410446-Drug Administration Schedule,
pubmed-meshheading:16410446-Female,
pubmed-meshheading:16410446-Humans,
pubmed-meshheading:16410446-Lymphoma, AIDS-Related,
pubmed-meshheading:16410446-Male,
pubmed-meshheading:16410446-Middle Aged,
pubmed-meshheading:16410446-Neoplasm Staging,
pubmed-meshheading:16410446-Prednisolone,
pubmed-meshheading:16410446-Risk Assessment,
pubmed-meshheading:16410446-Survival Analysis,
pubmed-meshheading:16410446-Vincristine
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy.
|
| pubmed:affiliation |
Institut Universitaire d'Hématologie-GELA, INSERM U728-Hôpital Saint Louis-AP-HP-1, Avenue Claude Vellefaux, 75010 Paris, France. nicolas.mounier@sls.ap-hop-paris.fr
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|